Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

We recently published a list of Jeff Smith’s Top 10 Activist Targets and Their Returns Compared to the S&P 500. In this ...

It's been a tough start to 2025 for investors amid concerns regarding the strength of the U.S. economy and uncertainties over ...

We recently published a list of 15 Best Large-Cap Value Stocks to Buy as the Recession Hits. In this article, we are going to take a look at where Pfizer Inc. (NYSE:PFE) stands against other best ...

Pfizer discontinues development of weight-loss pill. Investors now expect it to acquire VKTX to expand in the anti-obesity ...

Pfizer (NYSE: PFE) recently reminded investors how risky the drug-development business can be. On April 14, the company told investors it would scrap development of danuglipron, its oral GLP-1 ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) yesterday and set a price target of $30.00. The ...

TD Cowen analyst Steve Scala maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The company’s ...

Pfizer (PFE) stock slips as the company halts development of danuglipron for weight loss due to liver injury concerns. Read ...

With trade war volatility off the charts, investors are hunting for safety in safe dividend stocks. That’s because dividend ...

Dividend-paying stocks have consistently attracted investor interest due to their long-term value. CNBC highlights this by ...